PDCD1 and colorectal carcinoma: Our findings demonstrate that the administration of dasatinib combined with an anti-PD-1 antibody in an excluded-type CRC liver metastasis mouse model can reduce the amount of stroma in metastatic liver tumors and induce immune cell infiltration, thereby enhancing the therapeutic effect of the immune checkpoint inhibitors.